



How to say edasalonexent:

ē-dah-saloh-nex-ent

But we just call it edasa!

An overview of the PolarisDMD trial

We are currently enrolling a Phase 3 clinical trial, PolarisDMD, to study edasalonexent in Duchenne muscular dystrophy. We are enrolling boys ages 4 to 7 (up to 8th birthday), any mutation type, who have not been on steroids for at least 6 months. In PolarisDMD, two boys will receive edasalonexent for each boy who receives placebo, and study drug is provided as a gel capsule, taken 3 times per day with food. Boys may then have the opportunity to receive edasalonexent in our open-label extension, GalaxyDMD. Site visits for this Phase 3 clinical trial are once every 3 months, and travel costs are covered. For more information, please visit www.clinicaltrials.gov, or email DMDtrials@catabasis.com



Why edasalonexent (CAT-1004)

Edasalonexent inhibits NF-κB, a protein which plays a fundamental role in skeletal and cardiac muscle disease in Duchenne. By inhibiting NF-κB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasa is being developed as a potential stand-alone therapy and may have the potential to be combined with dystrophin-targeted therapies.



CLINICAL TRIAL RESULTS SEEN TO DATE WITH EDASALONEXENT

We studied edasalonexent in our Phase 2 MoveDMD trial and open-label extension. In this study we saw improvements in muscle function and markers of muscle health compared to an off-treatment control period. We also saw that boys grew similarly to boys who do not have Duchenne and that edasa was well-tolerated without known side effects of steroids.

Stay updated on our progress!

Join our mailing list: <http://www.catabasis.com/patients-families/for-further-information.php>

Follow us @CatabasisPharma.

Ask a question about the trial: DMDtrials@catabasis.com



The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy. Edasalonexent is an investigational drug that is not yet approved in any territory.